E. Clay

Cost-effectiveness analysis of pembrolizumab versus standard-of-care chemotherapy for first-line treatment of PD-L1 positive (>50%) metastatic squamous and non-squamous non-small cell lung cancer in France

C. Chouaïd, L. Bensimon, E. Clay et al. · Lung Cancer · 2018 · 71 citations · Full text

Medicine, Oncology, Pharmacoeconomics +17

Contribution of prolonged-release melatonin and anti-benzodiazepine campaigns to the reduction of benzodiazepine and z-drugs consumption in nine European countries

E. Clay, Bruno Falissard, Nicholas Moore et al. · European Journal of Clinical Pharmacology · 2012 · 65 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +15

Public health and economic impact of seasonal influenza vaccination with quadrivalent influenza vaccines compared to trivalent influenza vaccines in Europe

M. Uhart, Hélène Bricout, E. Clay et al. · Human Vaccines & Immunotherapeutics · 2016 · 58 citations · Full text

Veterinary Medicine, Infectious Diseases, Preventive Medicine +17

Public health impact and economic benefits of quadrivalent influenza vaccine in Latin America

Aurélien Jamotte, E. Clay, Bérengère Macabeo et al. · Human Vaccines & Immunotherapeutics · 2017 · 34 citations · Full text

Veterinary Medicine, Infectious Diseases, Preventive Medicine +17

Economic burden for Alzheimer’s disease in China from 2010 to 2050: a modelling study

E. Clay, Junwen Zhou, Zhan‐Miao Yi et al. · Journal of Market Access & Health Policy · 2019 · 33 citations · Full text

Social Sciences, Geriatric Medicine, Health Care Management +17